KLK3 and Familial prostate cancer: Finally, recent evidence in a phase I clinical trial has suggested that the proteasome inhibitor bortezomib has activity against human prostate cancer and reduces the expression of serum IL-6 and PSA levels in some patients (Papandreou and Logothetis, 2004).